CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: NMRAL1 (ImmuneEditome ID:57407)

1. Gene summary of enriched editing regions for NMRAL1

check button Gene summary
Gene informationGene symbol

NMRAL1

Gene ID

57407

GeneSynonymsHSCARG|SDR48A1
GeneCytomap

16p13.3

GeneTypeprotein-coding
GeneDescriptionnmrA-like family domain-containing protein 1|NmrA-like family domain containing 1|epididymis secretory sperm binding protein|short chain dehydrogenase/reductase family 48A, member 1
GeneModificationdate20230517
UniprotIDI3L2U0;I3L1Y8;I3L543;Q9HBL8;I3L1Q7;I3L3Z0;I3L0Y6
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:4462173-4463185:-ENST00000573533.1ENSG00000153406.12NMRAL1ncRNA_intronicFLAM_C,AluY,AluSx1,AluSqchr16:4462173-4463185:-.alignment
chr16:4467309-4468234:-ENST00000572391.1ENSG00000153406.12NMRAL1ncRNA_intronicAluSx1,MLT1D,AluSpchr16:4467309-4468234:-.alignment
chr16:4467309-4468234:-ENST00000575002.4ENSG00000153406.12NMRAL1ncRNA_intronicAluSx1,MLT1D,AluSpchr16:4467309-4468234:-.alignment
chr16:4471376-4473260:-ENST00000573520.4ENSG00000153406.12NMRAL1exonicAluSq2,AluJb,AluSx,L1MB7chr16:4471376-4473260:-.alignment
chr16:4471376-4473260:-ENST00000573571.1ENSG00000153406.12NMRAL1exonicAluSq2,AluJb,AluSx,L1MB7chr16:4471376-4473260:-.alignment


Top

2. Tumor-specific enriched editing regions for NMRAL1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000153406.12,NMRAL1BRCAEAG4.7609e-02image
ENSG00000153406.12,NMRAL1HNSCEAG4.6107e-02image
ENSG00000153406.12,NMRAL1KIRPEAG1.9155e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr16:4462173-4463185:-KIRPEER6.8794e-044.1580e-031.9655e-04image
ENSG00000153406.12,NMRAL1KIRPEAG3.1360e-035.0795e-032.4221e-04image
chr16:4462173-4463185:-PAADEER2.5691e-034.8183e-022.9823e+01image
ENSG00000153406.12,NMRAL1STADEAG1.9047e-021.7476e-021.1452e+01image

Top

3. Enriched editing regions and immune related genes for NMRAL1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:4462173-4463185:-TGCTEERENSG00000134352,IL6ST0.49903.2096e-073.1046e-110.5191imageNCPSF6;DDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SF3B4;SRSF1;TROVE2;U2AF1;U2AF2IL6STT_cells_CD4_memory_restingGSVA_HALLMARK_DNA_REPAIR
chr16:4462173-4463185:-TGCTEERENSG00000139926,FRMD60.47334.7102e-071.2909e-070.4242imageNDDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SRSF1;TROVE2;U2AF1;U2AF2NAB_cells_naiveGSVA_HALLMARK_HYPOXIA
chr16:4462173-4463185:-TGCTEERENSG00000173801,JUP0.48656.5470e-071.1295e-080.4551imageNCPSF6;DDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;SF3B4;SRSF1;TROVE2;U2AF1;U2AF2JUPB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr16:4462173-4463185:-TGCTEERENSG00000175106,TVP23C-0.48181.1710e-061.7520e-07-0.4201imageNCPSF6;DDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SF3B4;SRSF1;U2AF1;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
chr16:4462173-4463185:-TGCTEERENSG00000261663,RP11-304L19.11-0.47731.1891e-066.4674e-08-0.4333imageNDDX54;IGF2BP2NAT_cells_CD4_memory_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr16:4462173-4463185:-TGCTEERENSG00000165806,CASP70.47711.6696e-064.1539e-090.4669imageNDDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SF3B4;SRSF1;TROVE2;U2AF1;U2AF2CASP7T_cells_CD4_memory_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr16:4462173-4463185:-TGCTEERENSG00000114127,XRN10.45981.8273e-061.0526e-080.4559imageNCPSF6;DDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SF3B4;SRSF1;TROVE2;U2AF1;U2AF2NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr16:4462173-4463185:-TGCTEERENSG00000116898,MRPS15-0.46801.9965e-064.5966e-08-0.4377imageNCPSF6;DDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SF3B4;SRSF1;TROVE2;U2AF1;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr16:4462173-4463185:-TGCTEERENSG00000111145,ELK30.46102.6881e-066.0292e-080.4342imageNEIF4A3;FBL;FMR1;FUS;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;SRSF1;U2AF1;U2AF2NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr16:4462173-4463185:-TGCTEERENSG00000174915,PTDSS2-0.44663.7266e-065.1461e-07-0.4053imageNCPSF6;DDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SF3B4;SRSF1;TROVE2;U2AF1;U2AF2NADendritic_cells_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

4. Enriched editing regions and immune related splicing for NMRAL1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:4462173-4463185:-
SKCMEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.45421.5502e-176.1325e-21-0.4321imageNCPSF6;DDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SF3B4;SRSF1;TROVE2;U2AF1;U2AF2PRKCSHT_cells_CD8GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000153406.12,NMRAL1
SKCMEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.44471.0369e-161.7053e-20-0.4267imageNACIN1;ALYREF;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184PRKCSHT_cells_CD8GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr16:4462173-4463185:-
TGCTEERESENSG00000162910.14chr1228108246:228108321:228108436:228109021:228109148:2281092780.29763.3049e-036.3219e-060.4139imageNCPSF6;DDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;FXR2;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SF3B4;SRSF1;TROVE2;U2AF1;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_GLYCOLYSIS
ENSG00000153406.12,NMRAL1
TGCTEAGIRENSG00000174720.11chr4112646790:112647549:112647689:112647834-0.44673.9144e-051.2198e-09-0.4823imageNACIN1;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM22;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
ENSG00000153406.12,NMRAL1
TGCTEAGA3ENSG00000187607.11chr1715708154:15708247:15716058:15716109:15715999:157161090.31622.2035e-032.8941e-060.4423imageNACIN1;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
ENSG00000153406.12,NMRAL1
TGCTEAGA5ENSG00000185917.9chr2136036084:36036251:36038149:36038273:36036517:360382730.39132.2150e-042.4421e-060.4057imageNACIN1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr16:4462173-4463185:-
TGCTEERA3ENSG00000130751.5chr1947040443:47040550:47041024:47041125:47040977:470411250.30444.6795e-032.9521e-070.4676imageNCPSF6;DDX3X;DDX54;EIF4A3;FBL;FMR1;FUS;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;PRPF8;RBM10;SF3B4;SRSF1;U2AF1;U2AF2NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
ENSG00000153406.12,NMRAL1
TGCTEAGESENSG00000100150.12chr2231857444:31857553:31861367:31861433:31870589:31870744-0.30193.2914e-031.0592e-06-0.4614imageNACIN1;ALYREF;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
ENSG00000153406.12,NMRAL1
TGCTEAGESENSG00000167302.5chr1781231861:81232021:81232314:81232518:81233431:812335030.41839.0908e-054.5879e-090.4717imageNAUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
ENSG00000153406.12,NMRAL1
TGCTEAGESENSG00000173875.9chr1912610957:12611082:12612225:12612365:12623699:12623826-0.25445.6225e-031.5971e-05-0.4094imageNALYREF;AUH;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

5. Enriched editing regions and immune infiltration for NMRAL1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr16:4462173-4463185:-BLCAEERB_cells_memory1.0113e-03-0.1813image
ENSG00000153406.12,NMRAL1BLCAEAGB_cells_memory6.4762e-04-0.1877image
chr16:4462173-4463185:-BRCAEERMacrophages_M11.3079e-030.1005image
ENSG00000153406.12,NMRAL1BRCAEAGMacrophages_M11.6887e-040.1166image
chr16:4462173-4463185:-CESCEERB_cells_naive3.6727e-02-0.1247image
ENSG00000153406.12,NMRAL1CESCEAGB_cells_naive3.7367e-02-0.1240image
chr16:4462173-4463185:-COADEERMast_cells_activated4.6059e-020.1385image
ENSG00000153406.12,NMRAL1COADEAGMast_cells_activated8.2299e-030.1810image
chr16:4462173-4463185:-ESCAEERMacrophages_M28.8314e-040.2696image
ENSG00000153406.12,NMRAL1ESCAEAGMacrophages_M23.0714e-040.2870image
chr16:4462173-4463185:-GBMEERMacrophages_M04.5902e-03-0.2733image
ENSG00000153406.12,NMRAL1GBMEAGNK_cells_activated1.0590e-020.2428image
chr16:4462173-4463185:-HNSCEERPlasma_cells4.0612e-06-0.2186image
ENSG00000153406.12,NMRAL1HNSCEAGPlasma_cells5.1777e-06-0.2163image
chr16:4462173-4463185:-KIRCEERMast_cells_activated8.4072e-030.1757image
ENSG00000153406.12,NMRAL1KIRCEAGMast_cells_activated3.6388e-030.1878image
ENSG00000153406.12,NMRAL1KIRPEAGNK_cells_activated3.9972e-02-0.1332image
ENSG00000153406.12,NMRAL1LAMLEAGMast_cells_activated8.3139e-030.4020image
chr16:4462173-4463185:-LGGEERMast_cells_resting5.7225e-03-0.2384image
ENSG00000153406.12,NMRAL1LGGEAGMast_cells_resting4.1534e-03-0.2227image
chr16:4462173-4463185:-LIHCEERMast_cells_resting1.3841e-020.2330image
ENSG00000153406.12,NMRAL1LIHCEAGDendritic_cells_activated3.6684e-020.1821image
chr16:4462173-4463185:-LUADEERT_cells_CD4_memory_activated5.8340e-040.1694image
ENSG00000153406.12,NMRAL1LUADEAGT_cells_CD84.7252e-040.1706image
chr16:4462173-4463185:-LUSCEERB_cells_naive1.6194e-03-0.1521image
ENSG00000153406.12,NMRAL1LUSCEAGB_cells_naive1.8843e-03-0.1500image
chr16:4462173-4463185:-OVEERMacrophages_M14.6255e-020.1339image
chr16:4471376-4473260:-OVEERDendritic_cells_activated3.7151e-020.2571image
chr16:4462173-4463185:-PAADEERT_cells_follicular_helper6.3070e-030.2393image
ENSG00000153406.12,NMRAL1PAADEAGT_cells_follicular_helper5.4375e-030.2407image
chr16:4462173-4463185:-PCPGEERMacrophages_M01.1168e-020.3038image
ENSG00000153406.12,NMRAL1PCPGEAGMacrophages_M11.9209e-020.2438image
chr16:4462173-4463185:-PRADEERPlasma_cells2.0981e-04-0.1821image
ENSG00000153406.12,NMRAL1PRADEAGPlasma_cells6.8884e-04-0.1640image
chr16:4462173-4463185:-READEERMast_cells_activated1.4491e-030.3440image
ENSG00000153406.12,NMRAL1READEAGMast_cells_activated8.1764e-030.2885image
chr16:4462173-4463185:-SARCEERMacrophages_M11.9682e-020.1942image
ENSG00000153406.12,NMRAL1SARCEAGMacrophages_M14.9133e-020.1626image
chr16:4462173-4463185:-SKCMEERT_cells_CD81.4910e-070.2500image
ENSG00000153406.12,NMRAL1SKCMEAGT_cells_CD84.1416e-070.2407image
chr16:4462173-4463185:-STADEERDendritic_cells_activated4.0223e-020.1271image
chr16:4471376-4473260:-STADEERNK_cells_resting1.6536e-030.2754image
chr16:4462173-4463185:-TGCTEERT_cells_CD4_memory_resting4.8542e-030.2343image
ENSG00000153406.12,NMRAL1TGCTEAGT_cells_CD4_memory_resting4.8833e-030.2342image
chr16:4462173-4463185:-THCAEERMacrophages_M22.0822e-02-0.1638image
chr16:4462173-4463185:-THYMEERMacrophages_M13.6397e-030.3068image
ENSG00000153406.12,NMRAL1THYMEAGT_cells_follicular_helper1.1603e-02-0.2621image
chr16:4462173-4463185:-UCECEERMacrophages_M03.4838e-02-0.1675image
chr16:4462173-4463185:-UCSEERT_cells_CD4_memory_resting4.8516e-02-0.2777image
ENSG00000153406.12,NMRAL1UCSEAGT_cells_CD4_memory_resting4.4883e-02-0.2821image


Top

6. Enriched editing regions and immune gene sets for NMRAL1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
ENSG00000153406.12,NMRAL1BRCAEAG4.6289e-02image9.4786e-050.1210image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr16:4462173-4463185:-OVEER9.6259e-030.17342.5318e-020.15017.7216e-030.17848.6214e-040.2221image
ENSG00000153406.12,NMRAL1OVEAG2.1104e-020.15203.6092e-020.13831.2285e-020.16493.9408e-040.2318image
chr16:4462173-4463185:-SARCEER2.6010e-02-0.18554.7554e-02-0.16541.0196e-02-0.21354.7230e-020.1656image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000153406.12,NMRAL1BLCAGSVA_HALLMARK_COMPLEMENTEAG3.5012e-080.2991image
chr16:4462173-4463185:-BLCAGSVA_HALLMARK_COMPLEMENTEER1.0789e-070.2891image
chr16:4462173-4463185:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.7862e-110.2039image
ENSG00000153406.12,NMRAL1BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.8550e-110.2067image
ENSG00000153406.12,NMRAL1CESCGSVA_HALLMARK_KRAS_SIGNALING_UPEAG1.3899e-040.2250image
chr16:4462173-4463185:-CESCGSVA_HALLMARK_KRAS_SIGNALING_UPEER1.3081e-040.2262image
chr16:4462173-4463185:-COADGSVA_HALLMARK_DNA_REPAIREER1.1337e-03-0.2242image
ENSG00000153406.12,NMRAL1COADGSVA_HALLMARK_DNA_REPAIREAG2.6443e-04-0.2481image
ENSG00000153406.12,NMRAL1ESCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG1.1244e-020.2038image
chr16:4462173-4463185:-ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.7376e-030.2362image
ENSG00000153406.12,NMRAL1GBMGSVA_HALLMARK_MYC_TARGETS_V2EAG3.3845e-02-0.2025image
chr16:4462173-4463185:-GBMGSVA_HALLMARK_MYC_TARGETS_V2EER2.5847e-02-0.2165image
ENSG00000153406.12,NMRAL1HNSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.5409e-140.3540image
chr16:4462173-4463185:-HNSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.9352e-140.3556image
chr16:4462173-4463185:-KICHGSVA_HALLMARK_FATTY_ACID_METABOLISMEER4.1612e-020.4023image
ENSG00000153406.12,NMRAL1KIRCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.7473e-020.1539image
chr16:4462173-4463185:-KIRCGSVA_HALLMARK_PROTEIN_SECRETIONEER4.1174e-030.1910image
ENSG00000153406.12,NMRAL1KIRPGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.6366e-030.1941image
chr16:4462173-4463185:-KIRPGSVA_HALLMARK_NOTCH_SIGNALINGEER2.0703e-030.2016image
ENSG00000153406.12,NMRAL1LAMLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.0628e-030.4246image
chr16:4462173-4463185:-LGGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER4.7862e-020.1719image
ENSG00000153406.12,NMRAL1LGGGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG8.9085e-030.2036image
chr16:4462173-4463185:-LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.2229e-050.4020image
ENSG00000153406.12,NMRAL1LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.5293e-030.2732image
chr16:4462173-4463185:-LUADGSVA_HALLMARK_APOPTOSISEER1.9837e-080.2731image
ENSG00000153406.12,NMRAL1LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG6.0354e-090.2802image
chr16:4462173-4463185:-LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.7278e-090.2861image
ENSG00000153406.12,NMRAL1LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.6036e-100.2957image
ENSG00000153406.12,NMRAL1MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG6.5363e-030.3474image
chr16:4462173-4463185:-MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER5.5935e-030.3535image
ENSG00000153406.12,NMRAL1OVGSVA_HALLMARK_APICAL_JUNCTIONEAG2.2187e-040.2412image
chr16:4462173-4463185:-OVGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.1275e-040.2563image
chr16:4462173-4463185:-PAADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER8.9154e-030.2294image
ENSG00000153406.12,NMRAL1PAADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG9.2811e-030.2256image
ENSG00000153406.12,NMRAL1PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.4383e-020.2346image
ENSG00000153406.12,NMRAL1PRADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG3.1235e-030.1430image
chr16:4462173-4463185:-PRADGSVA_HALLMARK_HEME_METABOLISMEER3.2017e-040.1768image
chr16:4462173-4463185:-READGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER2.0768e-02-0.2535image
ENSG00000153406.12,NMRAL1READGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.2578e-02-0.2501image
chr16:4462173-4463185:-SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7112e-030.2591image
ENSG00000153406.12,NMRAL1SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.4003e-030.2336image
chr16:4462173-4463185:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8686e-070.2481image
ENSG00000153406.12,NMRAL1SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3400e-070.2504image
chr16:4471376-4473260:-STADGSVA_HALLMARK_HYPOXIAEER4.2414e-020.1797image
ENSG00000153406.12,NMRAL1STADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG1.1128e-050.2588image
chr16:4462173-4463185:-STADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER5.0845e-040.2137image
ENSG00000153406.12,NMRAL1TGCTGSVA_HALLMARK_GLYCOLYSISEAG4.1215e-04-0.2915image
chr16:4462173-4463185:-TGCTGSVA_HALLMARK_GLYCOLYSISEER5.5483e-04-0.2852image
ENSG00000153406.12,NMRAL1THCAGSVA_HALLMARK_APICAL_JUNCTIONEAG5.5701e-030.1838image
chr16:4462173-4463185:-THCAGSVA_HALLMARK_APICAL_JUNCTIONEER2.6425e-020.1574image
chr16:4462173-4463185:-THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER6.7269e-050.4118image
ENSG00000153406.12,NMRAL1THYMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.8629e-040.3801image
ENSG00000153406.12,NMRAL1UCECGSVA_HALLMARK_APICAL_SURFACEEAG1.7535e-040.2915image
chr16:4462173-4463185:-UCECGSVA_HALLMARK_APICAL_SURFACEEER1.6464e-040.2945image
chr16:4462173-4463185:-UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.6429e-040.4724image
ENSG00000153406.12,NMRAL1UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.2673e-040.4684image


Top

7. Enriched editing regions and drugs for NMRAL1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000153406.12,NMRAL1ACCJNK.Inhibitor.VIIIEAG2.2780e-02-0.3895image
chr16:4462173-4463185:-BLCAElesclomolEER7.4933e-060.2452image
ENSG00000153406.12,NMRAL1BLCAElesclomolEAG9.7596e-060.2418image
chr16:4462173-4463185:-BRCABMS.708163EER1.0079e-04-0.1215image
ENSG00000153406.12,NMRAL1BRCADMOGEAG1.7038e-04-0.1166image
ENSG00000153406.12,NMRAL1CESCCI.1040EAG2.3833e-04-0.2172image
chr16:4462173-4463185:-CESCCI.1040EER2.3419e-04-0.2178image
chr16:4462173-4463185:-CHOLAMG.706EER2.0785e-020.4009image
ENSG00000153406.12,NMRAL1CHOLAMG.706EAG2.1148e-020.3998image
chr16:4462173-4463185:-COADBMS.708163EER1.9709e-03-0.2134image
ENSG00000153406.12,NMRAL1COADBMS.708163EAG3.1208e-05-0.2819image
ENSG00000153406.12,NMRAL1ESCAMethotrexateEAG1.7879e-030.2497image
chr16:4462173-4463185:-ESCABicalutamideEER1.2763e-02-0.2036image
chr16:4471376-4473260:-ESCAImatinibEER4.0110e-02-0.2460image
chr16:4462173-4463185:-GBMAS601245EER1.4244e-04-0.3612image
ENSG00000153406.12,NMRAL1GBMAS601245EAG1.1598e-04-0.3593image
ENSG00000153406.12,NMRAL1HNSCCI.1040EAG3.5761e-07-0.2409image
chr16:4462173-4463185:-HNSCCI.1040EER4.5111e-07-0.2388image
ENSG00000153406.12,NMRAL1KICHABT.263EAG3.3605e-02-0.4101image
chr16:4462173-4463185:-KICHABT.263EER3.5909e-02-0.4132image
chr16:4462173-4463185:-KIRCAG.014699EER6.2810e-040.2267image
ENSG00000153406.12,NMRAL1KIRCCI.1040EAG3.5476e-03-0.1883image
chr16:4462173-4463185:-KIRPCytarabineEER2.5059e-030.1980image
ENSG00000153406.12,NMRAL1KIRPEmbelinEAG3.3455e-03-0.1895image
ENSG00000153406.12,NMRAL1LAMLA.770041EAG7.5627e-03-0.4064image
chr16:4462173-4463185:-LGGGDC.0449EER6.8548e-030.2334image
ENSG00000153406.12,NMRAL1LIHCBleomycinEAG4.2085e-040.3083image
chr16:4462173-4463185:-LIHCBleomycinEER3.5132e-050.3904image
ENSG00000153406.12,NMRAL1LUADBMS.509744EAG5.2774e-06-0.2211image
chr16:4462173-4463185:-LUADEmbelinEER4.2470e-06-0.2252image
chr16:4462173-4463185:-LUSCCI.1040EER2.4987e-07-0.2465image
ENSG00000153406.12,NMRAL1LUSCCI.1040EAG4.8814e-07-0.2406image
ENSG00000153406.12,NMRAL1OVJNK.9LEAG1.4917e-04-0.2475image
chr16:4471376-4473260:-OVGNF.2EER4.5306e-020.2473image
chr16:4462173-4463185:-OVJNK.9LEER6.0435e-05-0.2659image
chr16:4462173-4463185:-PAADABT.263EER1.3131e-02-0.2196image
ENSG00000153406.12,NMRAL1PAADAZD7762EAG1.4962e-02-0.2122image
ENSG00000153406.12,NMRAL1PCPGDMOGEAG2.1637e-03-0.3158image
chr16:4462173-4463185:-PCPGBMS.708163EER2.0674e-020.2781image
ENSG00000153406.12,NMRAL1PRADBIRB.0796EAG1.0629e-030.1582image
chr16:4462173-4463185:-PRADGW.441756EER6.2024e-040.1683image
chr16:4462173-4463185:-READFH535EER7.0290e-03-0.2938image
ENSG00000153406.12,NMRAL1READFH535EAG7.1447e-03-0.2932image
chr16:4462173-4463185:-SARCA.443654EER1.0375e-040.3178image
ENSG00000153406.12,NMRAL1SARCA.443654EAG1.9471e-040.3026image
chr16:4462173-4463185:-SKCMDMOGEER4.9650e-05-0.1944image
ENSG00000153406.12,NMRAL1SKCMDMOGEAG2.1434e-05-0.2029image
ENSG00000153406.12,NMRAL1STADCGP.60474EAG1.9289e-03-0.1842image
chr16:4471376-4473260:-STADCytarabineEER4.3242e-020.1790image
chr16:4462173-4463185:-STADKU.55933EER1.5314e-04-0.2322image
ENSG00000153406.12,NMRAL1TGCTAKT.inhibitor.VIIIEAG4.2299e-07-0.4080image
chr16:4462173-4463185:-TGCTAKT.inhibitor.VIIIEER5.1258e-07-0.4053image
ENSG00000153406.12,NMRAL1THCABIBW2992EAG1.3459e-04-0.2513image
chr16:4462173-4463185:-THCABIBW2992EER1.0783e-04-0.2710image
ENSG00000153406.12,NMRAL1THYMJNJ.26854165EAG2.7966e-03-0.3082image
chr16:4462173-4463185:-THYMAKT.inhibitor.VIIIEER9.3700e-04-0.3467image
ENSG00000153406.12,NMRAL1UCECAKT.inhibitor.VIIIEAG1.3398e-03-0.2507image
chr16:4462173-4463185:-UCECAKT.inhibitor.VIIIEER1.3662e-03-0.2518image
chr16:4462173-4463185:-UCSCI.1040EER8.2510e-03-0.3660image
ENSG00000153406.12,NMRAL1UCSCI.1040EAG9.0282e-03-0.3621image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType